29 November 2017 - Phase 3 trial initiation planned for first quarter 2018.

Idera Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for the company’s lead development candidate IMO-2125 in combination with ipilimumab for the treatment of anti-PD-1 refractory metastatic melanoma in combination with ipilimumab therapy.

IMO-2125 is a toll-like receptor 9 agonist that received orphan drug designation from the FDA in 2017 for the treatment of melanoma Stages IIb to IV. It signals the immune system to create and activate cancer-fighting cells (T-cells) to target solid tumors in refractory melanoma patients.

Read Idera Pharmaceuticals press release